India’s Covid-19 diplomacy could be gaining ground again. Hydroxychloroquine is regaining its credibility after WHO restarted its trials. Supply of HCQ to dozens of countries was an important part of India’s medical diplomacy. A global controversy regarding the drug and its efficacy as a prophylactic against Covid-19 or even as a treatment began with studies questioning its use. Many studies also hinted it could increase mortality rates among patients with a heart condition. India has remained steadfast in recommending its use as a preventive tool for frontline those in direct contact with Covid-19 patients.